A multicenter experience using adipose-derived mesenchymal stem cell therapy for cats with chronic, non-responsive...

Area of Science:

• Immunology
• Stem Cell Therapy
• Veterinary Medicine

Background:

• Mesenchymal stem cells (MSCs) show immune-modulating abilities, leading to trials for oral mucosal inflammation.
• Previous studies confirmed the safety and efficacy of fresh adipose-derived stem cells (ASCs) for feline gingivostomatitis (FCGS).

Purpose of the Study:

• Assess the feasibility of shipping ASCs for clinical use and commercialization.
• Expand safety and efficacy data for both shipped and non-shipped ASCs in FCGS cats.

Main Methods:

• Shipped and non-shipped ASCs were administered systemically to 18 FCGS cats.
• Evaluated ASC viability, phenotype, and function post-shipment.
• Monitored clinical response, immune cell populations (CD3+, CD20+, CD8+), and globulin levels.

Main Results:

• Shipped ASCs maintained viability, phenotype, and function.
• Systemic ASC administration achieved a 72% positive response rate.
• Responder cats showed reduced globulin levels, decreased oral CD3+ and CD20+ cells, and lower blood CD8^lo percentages.

Conclusions:

• Fresh feline ASCs can be successfully shipped and administered for FCGS treatment.
• ASCs modulate immune responses, proving effective for chronic oral inflammation linked to T cell activation.
• FCGS serves as a valuable large animal model for human oral inflammatory diseases.